Side Effects of Myeloma Treatments December 19, 2020 Myeloma Round Table image

Side Effects of Myeloma Treatments December 19, 2020 Myeloma Round Table

Dec 19, 2020

12:00PM - 02:00PM EST

Online Event

Overview

Understanding, Managing and Minimizing Side Effects of Treatment Sometimes the side effects of various myeloma treatments—chemotherapy, bone-strengthening drugs, monoclonal antibodies, transplant—can be as bad or worse than the disease itself. With the ever-growing range of treatment options, both minor and major side effects are part of the promise of potentially going into remission. The good news is that physicians and nurses have the tools and experience to anticipate, avoid and treat these side effects. Side effect mitigation is as important to patient care as every other part of treatment. The Myeloma Crowd Round Table Interactive Webcast on Saturday, December 19 will feature two myeloma experts who will discuss strategies and tips to help recognize and avoid adverse reactions to various treatments and procedures: Craig Hofmeister, MD, MPH, Winship Cancer Institute, Emory University, Atlanta, GA Suzanne Lentzsch, MD, PhD, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY The 90 minute program will begin at 12:00 pm Eastern Standard Time (9 am Pacific, 10 am Mountain, 11 am Central, 17:00 GMT, 18:00 CET). Each faculty member will speak for 20 minutes which will be followed by a 45 minute question and answer session open to all registered viewers. Todd Foster, HealthTree Head of Product, will describe and explain a new HealthTree profile feature that will be available called Side Effects Solutions that will be available in the New Year doing the final 30 minutes of the program. If you have any questions, please contact Greg Brozeit at greg@crowdcare.org or call 330-990-1090.

Highlights

Agenda

12:00 PM

Side Effects of Myeloma Treatment

Introduction

12:05 PM

Side Effects of Myeloma Treatment

* Understanding and managing myeloma bone disease issues * Avoiding and treating shingles (zoster) * Treatment-related rashes and neuropathy

12:25 PM

Side Effects of Myeloma Treatment

* Managing cytokine release syndrome (CRS) in novel therapies * Novel therapies, novel side effects * Primary infection with influenza and COVID

12:45 PM

Side Effects of Myeloma Treatment

Questions & Answers

01:35 PM

Health Tree: Side Effects Solutions Feature

Explaining a new feature to HealthTree profiles

01:55 PM

Side Effects of Myeloma Treatment

Closing Remarks

Speakers & Moderators

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

Todd Foster

Todd Foster is the Director of Digital Patient Engagement at HealthTree. He worked at MD Anderson Cancer Center for 12 years before helping myeloma patient, Jenny Ahlstrom, start up HealthTree. He specializes in patient experience, helping patients understand their options, and becoming decision makers with their care teams. Prior experience includes IT development projects at Intermountain HealthCare and UnitedHealthcare. Todd has a passion for using technology that can help patients have a better life, and along the way, help to further research for a cure.

Suzanne Lentzsch, MD, PhD

Suzanne Lentzsch, MD, PhD, is Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Service at the Columbia University Medical Center in New York. Her translational research focuses on identifying novel targets for the treatment of myeloma, myeloma bone disease, and AL amyloidosis. Dr. Lentzsch is a member of the National Cancer Institute’s Myeloma Steering Committee, the SWOG Myeloma Working Group, co-chairs the International Myeloma Society’s Career Development Committee, and serves as a grant reviewer for the Leukemia and Lymphoma Society and Stand Up 2 Cancer (SU2C) in collaboration with the American Association for Cancer Research. She will begin a four-year term in 2021 on the American Society of Hematology’s Scientific Committee on Plasma Cell Neoplasia and as Associate Editor for the Journal of Clinical Oncology. Prior to joining Columbia University, Dr. Lentzsch served as Clinical Director of the Multiple Myeloma Program at the University of Pittsburgh Cancer Institute (UPCI). She served a research fellowship to study the mechanism of action of thalidomide and its derivatives in multiple myeloma under the mentorship of Dr. Kenneth Anderson at the Dana-Farber Cancer Institute in Boston. She completed a fellowship and residency at the Humboldt University/Charité Berlin, Germany, where she earned her MD.

Ana Sahagun

Ana is an Engineer and a Psychotherapist, she has experience in both fields and loves them equally. She leads the Patient Experience Team at HealthTree and she’s passionate about talking to patients and empowering them. Whenever she’s not working you’ll find her exploring the world, eating different kinds of food, hiking or skiing.

Craig Hofmeister

Craig C. Hofmeister, MD, MPH, is Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Board certified in internal medicine and hematology, Dr. Hofmeister’s practice focuses on plasma cell cancers, including plasmacytomas, multiple myeloma, AL amyloidosis, smoldering myeloma, and monoclonal gammopathies of renal significance. He started practicing with Emory Healthcare in 2018.